Achieving remission and long-term success in inflammatory bowel disease (IBD) is greatly dependent on developing a treatment plan that incorporates therapies that induce mucosal healing, reduce inflammation and do not possess broad immunosuppressive properties. Get started in selecting the right therapeutic strategy for your patients by completing Insights on IBD: How Can We Achieve Long-Term Success?, a free, four-part — 15-minute each — educational series hosted by Neilanjan Nandi, MD.
After participating in the four-part, educational activity, participants should be able to:
- Apply guideline recommendations to optimize and individualize treatment for patients with IBD.
- Assess current pharmacotherapy for IBD in terms of safety, efficacy and tolerability profiles.
- Describe the role of treat-to-target strategies in improving long-term outcomes in patients with IBD.
- Formulate treatment adjustments in patients who have become nonresponsive, experience diminished response or become refractory to initial treatment for IBD.
- Assess emerging safety and efficacy data from clinical trials on biologic agents and small molecules that may potentially be used to treat IBD.
This series is provided by AGA and Prova Education, and supported by independent educational grants from AbbVie Inc., Bristol Myers Squibb and Takeda Pharmaceuticals.